Targeted therapies that complement specificgenetic aberrations are under investigation, including AURKA inhibitors in thosewith MYCN amplifications, BRAF inhibitors in those withBRAFV600E mutations and EGFR suppression, and AtaxiaTelangiectasia and Rad3-related inhibitors in patients with ATMmutations. Here, EGFR is linked to ataxia telangiectasia.